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Abstract 1 
It has become increasingly difficult to treat infections caused by Enterococcus  faecalis due to 2 
the high levels of intrinsic and acquired antibiotic resistances.  However, few studies have 3 
explored the mechanisms that E. faecalis employs to circumvent the host innate immune 4 
response and establish infection.  Capsule polysaccharides are important virulence factors that 5 
are associated with innate immune evasion.  We demonstrate that capsule producing E. faecalis 6 
strains of either serotype C or D are more resistant to complement-mediated opsonophagocytosis 7 
compared to un-encapsulated strains using cultured macrophages (RAW 264.7).  We show that 8 
differences in opsonophagocytosis are not due to variation in C3 deposition, but due to the ability 9 
of capsule to mask bound C3 from detection on the surface of E. faecalis.  Similarly, E. faecalis 10 
capsule masks detection of lipoteichoic acid which correlates with decreased TNF-α production 11 
by cultured macrophages in the presence of encapsulated strains compared to unencapsulated 12 
strains.  Our studies confirm the important role of the capsule as a virulence factor of E. faecalis, 13 
and provide several mechanisms by which the presence of the capsule influences evasion of the 14 
innate immune response, and suggest that the capsule could be a potential target for developing 15 
alternative therapies to treat E. faecalis infections. 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
3 
 
 1 
Introduction  2 
Enterocoocus faecalis is an important nosocomial pathogen associated with many types of 3 
infections including surgical site infections, bacteremia, urinary tract infections, and endocarditis 4 
(32).  Many infections caused by E. faecalis are difficult to treat due to increasing resistance to 5 
conventional antibiotic therapies including vancomycin (11-13).  Apart from studies on the roles 6 
of gelatinase and cytolysin (6, 23, 28), relatively little is known about the mechanisms employed 7 
by E. faecalis to circumvent host innate immune responses.  8 
 9 
In other bacterial pathogens, the production of capsular polysaccharide is a known virulence 10 
factor as it aids in avoidance of the host innate immune response (26, 31, 37).  E.  faecalis is 11 
known to produce two capsular polysaccharide serotypes (C and D)(11, 13, 15, 41) that 12 
contribute to pathogenesis and evasion of the host innate immune response (11).  Hufnagel et al. 13 
reported decreased neutrophilic killing of  encapsulated serotype C and D strains compared to the 14 
un-encapsulated A and B strains (16).  In addition, a recent comprehensive analysis of clinical E. 15 
faecalis isolates indicated that most pathogenic strains of E. faecalis belonged to serotypes C 16 
(20).  Despite a link between capsule and virulence, little is known about the specific 17 
mechanism(s) of how capsule enhances pathogenesis.  18 
 19 
The complement system plays a central role in the activation of the immune system and in the 20 
clearance of pathogens.  Cleavage of C3 to C3b provides a highly effective opsonin in the 21 
absence of antibodies.  Several reports have shown that capsule producing species of bacteria are 22 
more resistant to opsonophagocytosis by inhibiting the deposition and/or detection of C3b on the 23 
4 
 
surface of the organism (29, 33, 43).  Encapsulated bacteria employ numerous mechanisms to 1 
resist C3 opsonization and subsequent phagocytosis, including overall reduction in C3 deposition 2 
(7).  The abundance of C3 deposition is known to differ between capsule producing serotypes of 3 
Streptococcus pneumoniae (21).  In Staphylococcus aureus, C3 is buried beneath the surface of  4 
the capsule rendering C3 less accessible to complement receptors on the surfaces of 5 
macrophages and neutrophils (42).     6 
 7 
Bacterial capsular polysaccharides are also known to aid in the avoidance of innate immune 8 
responses including immune surveillance.  Immune surveillance relies on pathogen recognition 9 
receptors (PRRs), including Toll-like receptors, to sense pathogen associated molecular patterns 10 
(PAMPs).  Two common PAMPs associated with Gram-positive microorganisms are 11 
lipoteichoic acid (LTA) and peptidoglycan (PGN).  Detection of these PAMPs by Toll-like 12 
receptor 2 in conjunction with Toll-like receptors 1 and 6 induces the production of cytokines.  13 
In other instances, capsule prevents the detection of PAMPs by PRRs which leads to decreased 14 
or altered cytokine production (10).  The altered cytokine response to encapsulated  pathogens 15 
appears to contribute to pathogenicity and virulence.   16 
 17 
Our data indicate that the E. faecalis capsular polysaccharides from serotypes C and D attenuate 18 
C3 opsonized phagocytosis, and that this attenuated response is likely due to decreased 19 
recognition of bound C3 on the bacterial surface.  Similarly, capsule inhibits detection of E. 20 
faecalis LTA on the surface and the absence of recognition of this molecule and/or other surface 21 
PAMPs in the presence of capsule results in decreased TNF-α production by macrophages.    22 
 23 
5 
 
 1 
Material and Methods 2 
Bacterial Strains, plasmids, and growth conditions. All relevant bacterial strains are listed in 3 
table 1. E. faecalis strains were cultivated in Todd-Hewitt broth supplied with the appropriate 4 
antibiotics when needed (THB; Becton, Dickinson and Company, Sparks, Maryland).  5 
Culture of Macrophages.   6 
The macrophage like RAW 264.7 (ATCC TIB-71) cells were cultured in DMEM (Invitrogen, 7 
Grand Island, N.Y.) supplemented with 100 U penicillin per mL, 100 µg streptomycin per mL, 2 8 
μg L-glutamine per mL, and 5% heat inactivated fetal bovine serum (Atlanta Biologicals, 9 
Lawrenceville, GA).  10 
Complement C3 Deposition 11 
Overnight cultures of E. faecalis were diluted 1:100 in fresh media.  The cultures were allowed 12 
to reach mid-log phase (O.D. 600 of 0.6), and were washed 3X in sterile phosphate buffered 13 
saline (PBS) pH 7.4.  Approximately 2X107 cells of each strain were re-suspended in 10% 14 
normal CD1 mouse serum containing complement (Innovative Research, Southfield, MI) diluted 15 
in PBS.  Serum for negative controls was heat inactivated prior to the addition of bacteria by 16 
incubating at 56ºC for 30 minutes.  Bacteria were incubated in 10% serum for 30 minutes at 37ºC 17 
with agitation.  Complement deposition was stopped by addition of EDTA to a final 18 
concentration of 10mM followed by incubation on ice for 5 minutes.  The bacteria were pelleted 19 
at 4ºC, washed 3 times with sterile PBS to remove unbound complement, and finally re-20 
suspended in 30 µL of 1X SDS-PAGE loading buffer.  Whole bacteria were boiled vigorously 21 
for five minutes, and the cell debris was removed by centrifugation.  The remaining supernatants 22 
were loaded on an SDS-PAGE gel and electrophoresed.  Proteins in the gel were transferred to 23 
nylon membranes, and detection of C3 was carried out by western blot analysis using goat anti-24 
6 
 
mouse C3 polyclonal antibodies (Bethyl Laboratories, Montgomery, TX) and rabbit anti-goat 1 
conjugated with horse radish peroxidase (HRP) as secondary antibody (Bethyl Laboratories, 2 
Montgomery, TX) followed by development with SuperSignal® West Pico Chemiluminescent 3 
Substrate (Thermo Scientific, Rockford, IL).      4 
ELISA 5 
The concentration of naturally occuring anti-enterococcal antibodies present in the CD1 6 
(Innovative Research, Southfield, MI) mouse serum (used for subsequent phagocytosis assays) 7 
was analyzed by ELISA.  In addition, ELISA was performed to investigate the serotype 8 
specificity conferred by the presence of CpsF among E. faecalis isolates using serotype C-9 
specific antibodies.  Briefly, log phase E. faecalis strains were washed 3 times in PBS and 10 
aliquoted (50 L) into high binding 96 well Costar plates (Corning).  The washed cells were 11 
allowed to adhere overnight at 4C.  Bound cells were then incubated with either CD1 mouse 12 
serum or rabbit anti-serotype C serum (19) followed by incubation with either goat anti-mouse 13 
IgG HRP conjugate (Sigma, Saint Louis, MO) or goat anti-rabbit IgG HRP conjugate (Jackson 14 
ImmunoResearch, West Grove, PA).  ELISAs were developed using o-phenylenediamine 15 
dihydrochloride (OPD, Sigma) as the HRP substrate, and the results were read at O.D. 490 on a  16 
Bio-Tek PowerWave XS 96 well plate reader. 17 
 18 
Opsonophagocytosis assay 19 
E. faecalis strains V583, LT02 (V583 ΔcpsF), and LT06 (V583 ΔcpsC) were transformed by 20 
electroporation with the plasmid pMV158GFP (25) giving rise to LT12, LT13, and LT14 21 
respectively (Table 1).  Strains LT12, LT13, and LT14 constitutively express GFP allowing 22 
fluorescent detection during the opsonophagocytosis assay.    23 
7 
 
Log phase bacteria were washed three times in PBS prior to re-suspending in HBSS (Invitrogen) 1 
media.  Harvested RAW 264.7 cells were also re-suspended HBSS media.  A concentration of  2 
2X106 CFU/mL bacteria were added to 2X105 RAW 264.7 cells/mL followed by the addition of 3 
complement containing CD1 mouse serum to a concentration of 10% to give a final volume of 4 
500 µL and a bacteria to macrophage ratio of 10:1.  The samples were incubated at 37ºC for 20 5 
minutes to allow uptake of bacteria by macrophages.    Trypsin was then added at 0.25% final 6 
concentration and incubated for 10 minutes to remove any bacteria bound to the external surfaces 7 
of the RAW 264.7 cells.  The free bacteria were removed by three PBS washes with low speed 8 
centrifugation (750Xg) (8, 9).  The washed cells were fixed to glass slides by cyto-9 
centrifugation.  The samples were viewed under 100X oil immersion using a Ziess Axioplan 2 10 
fluorescent microscope to visualize the GFP expressing bacteria inside the RAW 264.7 cells.  11 
The intracellular bacteria of at least 100 RAW 264.7 cells were counted for each experimental 12 
replicate.  The phagocytic index was calculated by dividing the number of phagocytic cells (cells 13 
that had consumed bacteria) by the total number of macrophages counted and multiplying that 14 
number by the number of bacteria per phagocytic macrophage (  X 15 
) as previously described (22, 30).  Data are presented as percent phagocytic 16 
index with the phagocytic index of LT14 (V583ΔcpsC, capsule -) set to 100%.  Data were 17 
compiled from three separate experiments and the standard error of the mean and statistical 18 
significance were calculated with Graphpad Prism software.  19 
 20 
Slide Agglutination 21 
Un-encapsulated and encapsulated strains were tested for their reactivity to serotype A 22 
antiserum, previously reported to be specific for enterococcal lipoteichoic acid (LTA) (40).  23 
8 
 
Slide agglutination assays were preformed as previously described (19, 41). Briefly, log phase 1 
bacteria were washed three times with PBS. Following the PBS washes, 5.0 L of LTA 2 
antiserum or pre-immune serum was added to 15.0 L of test cells on a glass slide, and gently 3 
rotated for one minute.  Agglutination was determined by visual clumping of the cells.  Sterile 4 
PBS and pre-immune serum were used as negative controls. 5 
 6 
Flow Cytometry 7 
Flow cytometry was used to determine if C3 or LTA accessibility to antibodies was altered by 8 
the presence of capsule.  Log phased bacteria were washed three times in PBS, diluted 1:2, and 9 
blocked in 5% donkey serum (Jackson ImmunoResearch).  Bacteria used for analyzing C3 10 
accessibility were incubated in 50 µL of CD1 mouse serum for 20 minutes at 37ºC to allow for 11 
C3 deposition and washed three times in PBS prior to blocking with donkey serum.  Blocked 12 
cells were incubated for 15 minutes on ice with 2.0% goat anti-C3 antibodies followed by three 13 
washes in PBS.  Similarly diluted goat serum was used as an isotype control.  The bacteria were 14 
then incubated with FITC conjugated donkey anti-goat antibody (1:1000) (Jackson 15 
ImmunoResearch) for 15 minutes on ice in the dark.  The bacteria were again washed three times 16 
with PBS and analyzed by flow cytometry.  For detection of LTA accessibility, washed and 17 
blocked bacterial cells were incubated on ice for 15 minutes with 2.0% anti-LTA rabbit serum 18 
(40).  Similarly diluted pre-immune rabbit serum was used as an isotype control   Cells were then 19 
washed three times in PBS and incubated for 15 minutes on ice in the dark with FITC conjugated 20 
donkey anti-rabbit antibody (1:100) (Jackson ImmunoResearch).  Bacteria were washed three 21 
times in PBS and analyzed by flow cytometry.  For both the C3 and LTA experiments, flow 22 
cytometry analysis of 50,000 bacteria was performed using a FACSCalibur flow cytometer 23 
9 
 
(Becton and Dickinson, San Jose, CA) at a flow rate of ~2000 cells per second.  Data were 1 
analyzed using the WinList software program (VerityHouse, Topsham, ME). 2 
 3 
TNF-α production 4 
Log phase bacteria were washed three times in PBS and heat killed by incubation at 80ºC for 30 5 
minutes.  RAW 264.7 cells were harvested and re-suspended in fresh DMEM culture media to a 6 
concentration of 1X106 cells per mL.  RAW cells at a concentration of 1X106 cells/mL in a total 7 
volume of 2.0 mL were seeded in 24 well plates.  The cells were allowed to adhere to the plate 8 
surface for two hours prior to induction.  Bacteria were added to each well at a concentration of 9 
1X107 Cfu.  Lipopolysaccharide (LPS) from Salmonell enterica serotype typhimurium (Sigma) 10 
was used as a positive control for TNF-α production at a concentration of 10 ng per mL.  11 
Clarified supernatants were collected from each well at four hours after the bacterial inoculation.  12 
The amount of TNF-α present in the supernatants was determined by ELISA (eBioscience, San 13 
Diego, CA) following the manufacturer instructions.  One way ANOVA in correlation with a 14 
Newman-Kuels post hoc test were used to evaluate statistical significance (GraphPad Prism).   15 
 16 
Results 17 
 18 
Protective effects of capsule on opsonophagocytosis 19 
 20 
The capsular polysaccharides of many bacterial species confer resistance to complement 21 
mediated opsonphagocytosis.  We examined whether E. faecalis capsule conferred resistance to 22 
C3 opsonophagocytosis mediated by macrophages.  We used ELISA to confirm that our 23 
complement source (CD-1 mouse serum) was free of detectable E. faecalis antibodies (Data not 24 
shown).  25 
 26 
10 
 
Previous studies have shown that E. faecalis opsonizing antibodies exist in normal human serum; 1 
however, these antibodies are only directed towards the un-encapsulated serotype A and B 2 
strains of E. faecalis (2, 15).  In view of these studies, we determined if E. faecalis capsule 3 
serotypes C or D conferred resistance to complement mediated opsonophagocytosis compared to 4 
an isogenic acapsular mutant.  The encapsulated E. faecalis strains LT12 (serotype C), LT13, an 5 
isogenic cpsF deletion mutant which results in the production of a serotype D capsular 6 
polysaccharide (40)  and LT14, an isogenic cpsC deletion mutant which is un-encapsulated (40) 7 
were compared.  For this assay, we followed the method of Drevets et al. (8, 9) which calls for 8 
trypsin treatment and subsequent washes to remove externally bound bacteria as opposed to 9 
antibiotic treatment with gentamicin which has been shown to be internalized by macrophages 10 
leading to antibiotic killing affects independent of macrophage activity (9).  Our data shows a 11 
50% reduction in the opsonophagocytosis of capsule producing strains by macrophages in the 12 
presence of complement compared to unencapsulated strains (Fig. 1).  These data also show that 13 
there is no statistical difference in opsonophagocytosis between isogenic serotype C (LT12) and 14 
serotype D (LT13) strains (Fig. 1), suggesting that the mere presence of capsule regardless of 15 
serotype provides protection against bacterial uptake by macrophages .      16 
 17 
Complement C3 deposition and surface accessibility 18 
Bacterial resistance to complement mediated opsonophagocytosis has been attributed to 19 
decreased amounts of C3 deposition on the surface of encapsulated strains (7).  We used western 20 
blot analysis to assess the abundance of complement C3 deposited on both encapsulated and un-21 
encapsulated E. faecalis strains.  Two encapsulated strains FA2-2 and LT01(FA2-2ΔcpsF) and 22 
two un-encapsulated LT05 (FA2-2ΔcpsC) and OG1RF strains were used in this experiment.  23 
11 
 
Complement C3 is composed of an α and a β chain (35).  The 75 kDa C3 β chain is left intact 1 
through the processing events of C3, and was used to determine differences in overall C3 2 
deposition.  Figure 2 shows the deposition of the 75 kDa β chain of C3 on different strains of E. 3 
faecalis.  There is no difference in the amount of C3 deposited on the surfaces of the un-4 
encapsulated strains OG1RF and LT05 when compared to the encapsulated V583 and LT01 5 
strains (Fig. 2).  The other detected fragments in this blot are known breakdown products of C3 6 
and C3b.    7 
 8 
The amount of complement deposition does not vary between strains, but the presence of 9 
complement on the encapsulated strains could be masked from detection by complement 10 
receptors leading to decreased phagocytosis. We used complement opsonized strains of V583 11 
(serotype C), LT02(V583ΔcpsF, serotype D) and LT06 (V583ΔcpsC, capsule -) in conjunction 12 
with flow cytometry to determine C3 surface accessibility to antibodies.  Our data show that C3 13 
deposited on the surface of LT06 is more detectable than C3 deposited on the surface of 14 
encapsulated strains V583 and LT02 (Fig. 3).  Statistical analysis using one-way ANOVA in 15 
conjunction with a Newman-Keuls post hoc test show a significant statistical difference (p-16 
values < 0.05) between V583 and LT06, and also between LT02 and LT06 (Fig. 3).  There was 17 
also a statistically significant difference between V583 and LT02 even though they appear to be 18 
equally resistant to complement mediated opsonophagocytosis (Fig. 1).  The basis for this 19 
difference is not known at the present time, but may relate to structural differences in the 20 
capsular polysaccharides between these two serotypes.  21 
 22 
 23 
12 
 
Lipoteichoic acid and capsule  1 
Lipoteichoic acid (LTA) and peptidoglycan are PAMPs present on E. faecalis that are known to 2 
stimulate the immune system through pathogen recognition receptors including TLR-2 (36).  The 3 
capsules produced by other bacteria shield PAMPs resulting in altered cytokine production (31).  4 
We examined differences in LTA accessibility between encapsulated and un-encapsulated strains 5 
by slide agglutination assays.  E. faecalis serotype A anti-serum is directed against enterococcal  6 
LTA (40).  We tested the ability of these antibodies to agglutinate either encapsulated or un-7 
encapsulated E. faecalis strains.  The encapsulated strains V583 (serotype C) and LT02(ΔcpsF, 8 
serotype D) were not agglutinated by the anti-serum, whereas the un-encapsulated strains 9 
LT06(ΔcpsC) and 12030 (serotype A reference strain) were both agglutinated (data not shown).   10 
 11 
As agglutinating antibodies are generally of the IgM class, we also used flow cytometry to 12 
quantify the differences of LTA availability to the IgG class. Strains V583, LT02, and LT06 13 
were incubated with Serotype A antiserum followed by a FITC conjugated secondary antibody.  14 
Figure 4A and B show the percentage of the cells that were positive for FITC labeling.  One-way 15 
ANOVA followed by a Newman-Keuls post hoc test showed significant statistical differences 16 
(p-values < 0.05) in the amount LTA detected between V583 (serotype C) and LT06 (capsule -), 17 
and also between LT02 (serotype D) and LT06.  However, there was no significant statistical 18 
difference when the encapsulated strains V583 and LT02 were compared.  These data indicate 19 
that capsule produced by either serotype C or D strains masks LTA from antibody detection. 20 
 21 
 22 
 23 
13 
 
TNF-α production in response to capsule 1 
The presence of a capsule is known to alter the macrophage cytokine response in other 2 
microorganisms (10).  To examine this possibility in E. faecalis, we used ELISA to assess the 3 
ability of capsule producing and non-producing strains to induce TNF-α production by RAW 4 
264.7 cells.  We predicted that the ability of capsule to inhibit detection of LTA (Fig. 4) would 5 
translate to less TNF-α production by RAW 264.7 cells.  The capsule producing strains T-5 6 
(serotype D), V583 (serotype C), LT02 (serotype D) along with the un-encapsulated strains 7 
(LT06, 12030, OG1RF) were heat-killed and incubated with RAW 264.7 cells.  Clarified 8 
supernatants were collected at 4 hours post inoculation, and were analyzed for TNF-α 9 
production.  The TNF-α produced in response to the un-encapsulated strains is significantly 10 
higher than that produced in response to encapsulated strains with p-values < 0.05 using one-way 11 
ANOVA and a Newman-Keuls post hoc test analysis (Fig. 5).  However, there is no statistically 12 
significant difference when comparing the encapsulated strains with each other or when 13 
comparing the un-encapsulated strains with each other.  Strikingly, there is no statistically 14 
significant difference in the amount of TNF-α produced by RAW cells when comparing the 15 
strains T-5, V583, and LT02 to the un-induced RAW control cells.        16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
14 
 
Discussion 1 
Capsular polysaccharides contribute to the virulence of microorganisms through multiple 2 
mechanisms including resistance to opsonophagocytosis, and by masking bacterial surface 3 
antigens from detection by the host immune system (1, 10).  Several Gram-positive cocci 4 
including S. aureus (26), S. pneumoniae (1), and group-B streptococci (4) produce capsular 5 
polysaccharides that are known to contribute to virulence.  Previous reports have indicated that 6 
E. faecalis strains can be classified by the presence or absence of capsular polysaccharide (11, 7 
15, 16, 40).  Hancock and Gilmore (11) showed that the presence of capsule enhances 8 
persistence at infectious sites using a murine infection model, and subsequently showed that 9 
encapsulation protects the bacteria from killing by neutrophils, whereas an unencapsulated 10 
isogenic mutant was readily killed by neutrophils.  The killing of the unencapsulated mutant by 11 
neutrophils was dependent on the opsonic activity of complement.   12 
 13 
Here, we demonstrate that E. faecalis capsular polysaccharide serotypes C and D provide 14 
resistance to complement opsonized phagocytosis by macrophages.  In good agreement with 15 
previously reported work on the role of the E. faecalis capsule in affecting resistance to opsonic 16 
killing by neutrophils (11, 16), we observed a 50% reduction in phagocytic killing in 17 
encapsulated strains compared to the isogenic acapsular mutant.  An additional cell wall 18 
polysaccharide in E. faecalis termed Epa has also been shown to contribute to resistance to 19 
phagocytic killing (38), and may account for why the protective affect of the capsule is not more 20 
substantial in E. faecalis.  Unlike the capsule, the Epa polymer and its genetic locus appear to be 21 
highly conserved in E. faecalis (11, 38).  A direct comparison on the relative contribution of Cps 22 
and Epa in the same strain background has not possible to date, because the OG1RF strain in 23 
15 
 
which Epa mutants were created lacks the capsule locus (15, 41), and in our hands we have been 1 
unable to generate Epa mutants in encapsulated strain backgrounds (L.T., unpublished data).  A 2 
recent report by Teng et al. (39) demonstrated gross changes in the bacterial cell shape of Epa 3 
mutants in the OG1RF background and this may account for our inability to generate such 4 
mutants in our encapsulated strains and may partially explain the pleiotropic affects ascribed to 5 
the Epa locus in virulence studies (39, 44).   6 
 7 
An additional benefit of the macrophage system is the use of cultured cells that are less likely to 8 
vary from experiment to experiment compared to the neutrophil assay, which requires fresh 9 
isolation of neutrophils from human blood donors.  Furthermore, because the strains used in this 10 
comparative study were isogenic derivatives we can make a direct assessment on the role of 11 
capsule and serotype differences in host immune evasion as has been observed in other microbial 12 
pathogens (29, 33, 43) 43).  Our findings show that E. faecalis capsular polysaccharides alter the 13 
detection of C3 and LTA by antibodies (Figs. 3-4).  Paralleling these findings, we also 14 
demonstrate that the presence of capsule also abrogates TNF-α production by macrophages (Fig. 15 
5).  Together these data provide a mechanism by which the presence of capsule alters 16 
complement-mediated opsonophagocytosis by altering accessibility of the bound C3b opsonin, 17 
as well as limiting the recruitment of phagocytes to sites of infection by altering the production 18 
of TNF-α in response to encapsulated E. faecalis.  It is noteworthy that capsule serotype 19 
differences in an isogenic background did not result in significant changes in resistance to 20 
opsonin-mediated phagocytosis, or in altered TNF-α response.  McBride et al. (20) recently 21 
showed that clinical isolates of E. faecalis possessing multiple virulence factors, as well as multi-22 
drug resistance were more likely to be identified as capsule serotype C.  Our findings suggest 23 
16 
 
that either of the encapsulated serotypes (C or D) benefit the bacterium in evasion of the host 1 
innate response.  We did however observe a significant difference in the amount of bound C3 2 
detectable on the surface of isogenic serotype C compared with serotype D capsule, but this 3 
difference did not correlate with changes in the phagocytic index of these strains, leaving open 4 
the question as to why the more pathogenic and drug-resistant clinical isolates are more 5 
frequently identified as serotype C as opposed to D.  In S. aureus, comparison of the contribution 6 
of type 5 and type 8 capsule in the same strain background revealed that the presence of N-7 
acetylation on the type 5 capsule structure conferred a fitness advantage in vivo (42).  Whether a 8 
similar affect will also be observed in the comparison of E. faecalis serotype C and D strains in 9 
vivo will be the focus of future studies.     10 
 11 
The mechanism by which capsule alters the phagocytic response in the presence of complement 12 
opsonization differs depending on the microorganism.  The capsule of group-B streptococci 13 
contains a sialic acid side chain that inactivates C3b, whereas the capsule serotypes 5 and 8 of S. 14 
aureus shield C3 from detection by the cognate receptors (4, 42).  In contrast, the presence of 15 
capsule in S. pneumoniae decreases the amount of complement deposited on the cell surface 16 
(21).  Our results suggest that the mechanism of evading opsonophagocytosis by encapsulated E. 17 
faecalis is dependent on the ability of the capsule to mask the bound C3b to prevent it from being 18 
recognized by host effector cell receptors targeted to bound complement.    19 
 20 
Aside from anti-phagocytic properties, bacterial capsules also act as barriers that limit detection 21 
of PAMPs by PRRs (1, 10).  A common PAMP shared by all strains of enterococci is LTA.  The 22 
LTA of E. faecalis is known to stimulate TNF-α production via TLR-2 and TNF-α is thought to 23 
17 
 
play a key role in E. faecalis-mediated inflammatory responses (3), though the full role of TNF-α 1 
in E. faecalis infections is not fully understood (27).  A study involving Enterococcus faecium, 2 
which produces serologically identical LTA to E. faecalis, showed that TLR-2 mediated 3 
signaling was critical for early immune response and clearance of E. faecium (18).  Based on 4 
these studies, recognition of enterococcal LTA and/or peptidoglycan by TLR-2 would appear 5 
critical for an efficient host immune response, and the masking of these integral wall components 6 
by capsule could result in increased pathogenesis by limiting the host response to the organism..  7 
Interestingly, a study by Kau et al. (17) demonstrated that the response to E. faecalis in a urinary 8 
tract infection model is not TLR-2 dependent.  The capsule phenotype of the clinical isolate used 9 
in this study is not known, and based on our finding that the presence of the capsule alters 10 
recognition of an important PAMP (LTA) known to be recognized by TLR-2, it would suggest 11 
that TLR-2 signaling might only be of benefit against E. faecalis strains that lack capsule. 12 
 13 
Our goal was to understand the mechanism of how encapsulation enhances the resistance of E. 14 
faecalis to innate immunity.  Taken together, our results show that the two capsule serotypes 15 
produced by E. faecalis can subvert host innate immune responses by conferring resistance to 16 
complement-mediated phagocytosis, as well as altering the innate response to the pathogen.  This 17 
study provides mechanistic evidence demonstrating that the E. faecalis capsule alters the 18 
accessibility of bound C3 supporting the observation that the most pathogenic lineages of E. 19 
faecalis are encapsulated (20, 40).  By masking PAMPs on the surface of E. faecalis, the capsule 20 
also alters the host response to infection by encapsulated strains.  It is our contention that the 21 
capsule produced by E. faecalis serotypes C and D is an important virulence determinant that 22 
18 
 
plays multi-faceted roles in evasion of host innate immune responses.  Because of this, we 1 
believe that the E. faecalis capsule could serve as a target for developing future therapeutics. 2 
 3 
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List of Figures 1 
Figure 1.  Capsule serotypes C and D are resistant to opsonophagocytosis in the presence of 2 
complement. A. Representative micrographs depicting from left to right LT12 (V583 expressing 3 
Gfp), LT13 (ΔcpsF expressing Gfp), and LT14 (ΔcpsC expressing Gfp) incubated with RAW 4 
264.7 macrophage like cells. B. Quantification of phagocytic index expressed as the percentage 5 
of the un-encapsulated LT14 strain (see Materials and Methods for calculating Phagocytic 6 
index). The light gray bar (LT12: serotype C) and the dark gray bar (LT13: serotype D) both 7 
show a significant reduction in phagocytic index when compared to LT14 (black bar).  Error bars 8 
represent SE of three replicates.   9 
Figure 2.  The amount of C3 deposition does not differ between strains.  Western blot analysis 10 
was employed to examine the amount of the C3 deposited on the cell surface of serotype C 11 
(FA2-2), serotype D (LT01), and un-encapsulated (LT05 and OG1RF) strains.  The blot shows 12 
the 75 kDa β chain of C3 for FA2-2 (A), LT02 (B), LT05 (C), OG1RF (D) ,and the negative 13 
control, FA2-2 incubated with heat inactivated serum (E).   14 
Figure 3.  Complement C3 is masked from detection by capsule.  Flow cytometry was used in 15 
conjunction with anti-C3 antibodies and FITC conjugated secondary antibodies to evaluate the 16 
availability of C3 to detection.  A. Representative histograms depicting (from left to right) flow 17 
cytometry results for serotype C (V583), seroypte D (LT02) and un-encapsulated (LT06) E. 18 
faecalis strains.  The isotype controls are light gray and the C3 antibody treated cells are dark 19 
gray.  B. Quantification of the C3 positive cells.  Using one-way ANOVA in conjunction with a 20 
Newman-Keuls post test, statistical analysis for three replicates showed statistically significant 21 
differences (p-value < 0.05) in the amount of positively labeled bacteria when V583 (light gray 22 
23 
 
bar) and LT06 (black bar) were compared, and when LT02 (dark gray bar) and LT06 were 1 
compared.  Statistical analysis also revealed a significant difference in C3 detection between 2 
V583 and LT02 (P < 0.05).  Error bars represent SE for three replicate. Approximately 50,000 3 
bacteria were analyzed for each replicate.  4 
Figure 4.  The presence of capsule masks LTA from detection by antibodies.  Flow cytometry 5 
was used in conjunction with LTA antiserum and FITC conjugated secondary antibodies to 6 
evaluate the levels of LTA accessibility.  A. Representative histograms depicting (from left to 7 
right) flow cytometry results for serotype C (V583), seroypte D (LT02) and un-encapsulated 8 
(LT06) E. faecalis strains.  The isotype controls are in light gray and the C3 antibody treated 9 
cells are dark gray.  B. Quantification of LTA detection by flow cytometry.  Statistical analysis 10 
for three replicates using a one-way ANOVA in conjunction with a Newman-Keuls post test 11 
showed significant differences (P < 0.05) in the amount of LTA detected between V583 (light 12 
gray bar) and LT06 (black bar), and between LT02 (dark gray bar) and LT06 with p-values less 13 
than 0.05.  However, there is no statistical difference in LTA detection when LT02 is compared 14 
V583.  Error bars represent SE for three replicate. Approximately 50,000 bacteria were analyzed 15 
for each replicate. 16 
Figure 5.  E. faecalis capsule reduces TNF-α production by RAW 264.7 cells.  Macrophage like 17 
RAW 264.7 cells were incubated with serotype C (V583), serotype D (T-5 and LT02), and un-18 
encapsulated (LT06, 12030, and OG1RF) E. faecalis strains.  Supernatants were collected and 19 
analyzed by ELISA for TNF-α content.  Results show pg/mL of TNF-α production by RAW 20 
264.7 cells in the presence of each strain.  Statistical analysis of three replicates using one way 21 
ANOVA and a Newman-Kuels post hoc test shows significant differences between the amount 22 
of TNF-α produced in response to T-5, V583 and LT02 when compared to LT06, 12030, and 23 
24 
 
OG1RF.  Interestingly, there is no statistically significant difference between the amount of 1 
TNF-α produced by un-induced RAW cells when compared to the three encapsulated strains.  2 
Error bars represent SE for three replicate experiments.  3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
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 12 
 13 
 14 
 15 
 16 
 17 
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Table 1 1 
Table 1: E. faecalis Strains used in this study 
Strain Description Reference 
FA2-2 Capsule + (Serotype C) (5) 
V583 Capsule + (Serotype C) (34) 
OG1RF Capsule -  (24) 
12030 Capsule - (14) 
LT01 FA2-2 ΔcpsF Capsule + (Serotype D) (41) 
LT02 V583 ΔcpsF Capsule + (Serotype D) (41) 
LT05 FA2-2 ΔcpsC Capsule - (41) 
LT06 V583 ΔcpsC Capsule - (41) 
LT12 V583 + pMV158gfp This Study 
LT13 LT02 + pMV158gfp This Study 
LT14 LT06 + pMV158gfp This Study 
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